EIF2A and early-onset autosomal dominant Alzheimer disease: Another UPR therapeutic target for NDDs is eIF2α which attenuates global protein synthesis rates critical for memory and neuronal function, when it is phosphorylated by phosphorylated-PERK; phosphorylated-eIF2α levels are elevated in Alzheimer’s disease and other NDDs [275, 276].